“As a widely respected hepatologist and 2011 President of the International Liver Cancer Association, Dr. Gores will contribute a wealth of clinical knowledge on hepatotoxicity and drug induced liver pathology to our Medical Advisory Board,” said Eamonn P. Hobbs, CEO and president of Delcath Systems in the release. “His insight will help provide valuable support to the commercialization of the Delcath Hepatic CHEMOSAT Delivery System in Europe and the rest of the world, as well as to our regulatory process in the United States.”
Dr. Gores’ research focuses on the basic mechanisms behind cell death in the liver and employing models to human disease. He has published more than 400 articles, chapters, reviews and editorials. Dr. Gores serves on the editorial boards for the American Journal of Physiology, American Journal of Gastroenterology and Nature Reviews in Clinical Gastroenterology and Hepatology.
Related Articles on Gastroenterology:
ASGE Recognizes 27 Endoscopy Units for Quality and Safety
Racial Disparity of Colorectal Cancer Mortality Rates Increased in Last 20 Years
Narrow Band Imaging Does Not Affect Detection Rate or Miss Rate in Colonoscopy
